Logo image of ENLV

ENLIVEX THERAPEUTICS LTD (ENLV) Stock Fundamental Analysis

NASDAQ:ENLV - Nasdaq - IL0011319527 - Common Stock - Currency: USD

1.14  +0.02 (+1.79%)

Fundamental Rating

3

ENLV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ENLV as it has an excellent financial health rating, but there are worries on the profitability. ENLV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENLV had negative earnings in the past year.
ENLV had a negative operating cash flow in the past year.
ENLV had negative earnings in each of the past 5 years.
In the past 5 years ENLV always reported negative operating cash flow.
ENLV Yearly Net Income VS EBIT VS OCF VS FCFENLV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ENLV has a Return On Assets (-59.60%) which is comparable to the rest of the industry.
ENLV has a Return On Equity (-69.45%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.6%
ROE -69.45%
ROIC N/A
ROA(3y)-59.69%
ROA(5y)-44.71%
ROE(3y)-71.64%
ROE(5y)-53.05%
ROIC(3y)N/A
ROIC(5y)N/A
ENLV Yearly ROA, ROE, ROICENLV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ENLV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENLV Yearly Profit, Operating, Gross MarginsENLV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENLV has more shares outstanding
Compared to 5 years ago, ENLV has more shares outstanding
ENLV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENLV Yearly Shares OutstandingENLV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENLV Yearly Total Debt VS Total AssetsENLV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ENLV has an Altman-Z score of -4.00. This is a bad value and indicates that ENLV is not financially healthy and even has some risk of bankruptcy.
ENLV has a Altman-Z score of -4.00. This is comparable to the rest of the industry: ENLV outperforms 44.50% of its industry peers.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4
ROIC/WACCN/A
WACCN/A
ENLV Yearly LT Debt VS Equity VS FCFENLV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 7.20 indicates that ENLV has no problem at all paying its short term obligations.
ENLV has a better Current ratio (7.20) than 66.67% of its industry peers.
ENLV has a Quick Ratio of 7.20. This indicates that ENLV is financially healthy and has no problem in meeting its short term obligations.
ENLV's Quick ratio of 7.20 is fine compared to the rest of the industry. ENLV outperforms 67.03% of its industry peers.
Industry RankSector Rank
Current Ratio 7.2
Quick Ratio 7.2
ENLV Yearly Current Assets VS Current LiabilitesENLV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.21% over the past year.
EPS 1Y (TTM)53.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ENLV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.58% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.26%
EPS Next 2Y8.43%
EPS Next 3Y-2.91%
EPS Next 5Y21.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENLV Yearly Revenue VS EstimatesENLV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 200M 400M 600M 800M
ENLV Yearly EPS VS EstimatesENLV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENLV. In the last year negative earnings were reported.
Also next year ENLV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENLV Price Earnings VS Forward Price EarningsENLV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENLV Per share dataENLV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

ENLV's earnings are expected to decrease with -2.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.43%
EPS Next 3Y-2.91%

More info and screens

0

5. Dividend

5.1 Amount

ENLV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENLIVEX THERAPEUTICS LTD

NASDAQ:ENLV (7/2/2025, 11:09:01 AM)

1.14

+0.02 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-23 2025-05-23
Earnings (Next)N/A N/A
Inst Owners13.43%
Inst Owner Change-7.25%
Ins Owners4.61%
Ins Owner ChangeN/A
Market Cap27.19M
Analysts82.5
Price Target10.2 (794.74%)
Short Float %0.33%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.6%
ROE -69.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.69%
ROA(5y)-44.71%
ROE(3y)-71.64%
ROE(5y)-53.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.2
Quick Ratio 7.2
Altman-Z -4
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)362.73%
Cap/Depr(5y)347.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.28%
EPS Next Y18.26%
EPS Next 2Y8.43%
EPS Next 3Y-2.91%
EPS Next 5Y21.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.41%
OCF growth 3YN/A
OCF growth 5YN/A